Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

 – September 1, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”) reported financial results for the three and six months ended June 30, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. “The second quarter was a very solid quarter in allContinue reading “Emerald Health Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update”

Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects

SYNC(TM) Nano Fast Action Spray uses nanoemulsion technology to enable rapid onset and shorter duration of effects; the first THC product is in-market, with CBD to follow  –  Emerald Health Therapeutics, Inc. (TSXV: EMH) (OTCQX: EMHTF) (“Emerald”)  has launched the first product in its adult-use SYNCTM Nano fast-acting cannabis spray product line. SYNCTM 15 Nano THC FastContinue reading “Emerald Health Therapeutics Launches New Fast-Acting Cannabis Spray Products Offering Consumers Significantly Improved Predictability and Control of Effects”

Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business

– July 31, 2020) – Emerald Health Therapeutics, Inc. (TSXV: EMH)  (“Emerald”) and Quinto Resources Inc. (“Quinto”) (TSXV: QIT) today announced that they have entered into a share purchase agreement dated July 30, 2020 (the “Agreement”) in respect of the sale of Emerald’s wholly-owned subsidiaries, Verdélite Sciences, Inc. (“Verdélite Sciences”) and Verdélite Property Holdings, Inc.Continue reading “Emerald Health Therapeutics and Quinto Resources Enter into Share Purchase Agreement for Sale of Quebec Cannabis Business”

Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba

Pure Sunfarms remains top-selling dried cannabis brand with Ontario Cannabis Store1 and achieves sales records in July — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has begun shipping branded, packaged dried flower products to Manitoba’s licensed private sector retailers, withContinue reading “Emerald Health Therapeutics’ Pure Sunfarms Joint Venture Begins Shipping Branded Products to Manitoba”

Emerald Health Therapeutics Announces Completion of Accordion Provision of Pure Sunfarms’ Credit Facility

Expanded facility provides additional financial resources and flexibility as Pure Sunfarms continues to build on its success to date as a leading Canadian cannabis producer and brand — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today announced that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has further expanded itsContinue reading “Emerald Health Therapeutics Announces Completion of Accordion Provision of Pure Sunfarms’ Credit Facility”

Emerald Health Therapeutics’ Verdélite Launches Souvenir™ Cannabis Brand in Québec

Verdélite offers craft cannabis products in its home province for Québec consumers  — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its Verdélite Sciences subsidiary in St. Eustache, Québec, has launched its new Souvenir cannabis brand in the province. The Souvenir product line initially consists of select dried flower products from two Emerald cultivars, Grapefruit GG4Continue reading “Emerald Health Therapeutics’ Verdélite Launches Souvenir™ Cannabis Brand in Québec”

Emerald Health Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

— Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) reported financial results for the quarter and ended March 31, 2020. Full versions of the Company’s unaudited condensed interim consolidated financial statements and MD&A can be found on SEDAR at www.sedar.com. “In the first quarter and year to date, the benefits of Emerald’s significant restructuring andContinue reading “Emerald Health Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update”

Emerald Health Therapeutics Announces Pure Sunfarms’ Initial Cultivation and Sales License for Second Greenhouse

Pure Sunfarms intends to launch vape products this summer VANCOUVER, British Columbia, May 25, 2020 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that its joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received from Health Canada its cannabis cultivation and sales licence based on an initialContinue reading “Emerald Health Therapeutics Announces Pure Sunfarms’ Initial Cultivation and Sales License for Second Greenhouse”

Emerald Announces $2.1 Million Prospectus Sale

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 21, 2020 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF), has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subjectContinue reading “Emerald Announces $2.1 Million Prospectus Sale”